Generic name |
ruxolitinib |
|
---|---|---|
Strength |
5 mg, 10 mg |
|
Form |
tablets |
Special Authority criteria |
Approval period |
|
Acute graft-versus-host disease (aGvHD) in adult and pediatric patients aged 12 years and older |
||
Initial coverage Patient has acute graft-versus-host disease (aGvHD) grade II to IV AND Has confirmed diagnosis of corticosteroid refractory or corticosteroid dependent aGvHD1 AND Patient must not be receiving treatment with systemic therapies for aGvHD (except for calcineurin inhibitors) AND The treatment is prescribed by a specialist physician with the BC Leukemia/Bone Marrow Transplant (BCL/BMT) program |
4 weeks |
|
Renewal coverage Patient has achieved an overall response (i.e., complete response, very good partial response, partial response, or stable disease with significant reduction in steroid doses) at Day 28 of treatment and maintains an ongoing clinical benefit |
12 weeks |
|
Chronic graft-versus-host-disease (cGvHD) in adults and pediatric aged 12 years and older |
||
Initial Patient has moderate to severe chronic graft-versus-host disease (cGvHD) according to National Institutes of Health (NIH) consensus criteria AND Patient has experienced inadequate response to corticosteroids2 or corticosteroids with other systemic therapies AND Patient must not be receiving additional treatment with systemic therapies for cGvHD (except for calcineurin inhibitors) AND The treatment is prescribed by a specialist physician with the BCL/BMT program |
24 weeks |
|
Renewal Patient has achieved an overall response (i.e., complete response, very good partial response, partial response, or stable disease with significant reduction in steroid doses), after 24 weeks of treatment and maintains an on-going clinical benefit |
24 weeks |